AOD 9604 10mg
EXPRESS Apple Pay afterpay
AOD-9604 at a glance
A modified 16-amino-acid hGH fragment
AOD-9604 is based on the 177-191 region of human growth hormone, with an additional N-terminal tyrosine. Unlike the full-length 191-amino-acid hormone, AOD-9604 is a much shorter molecule investigated for selected metabolic properties.
The peptide contains two cysteine residues connected by a disulphide bond. This structural feature forms part of the molecule’s defined chemical identity.
Lipolysis research
Preclinical investigations have measured the breakdown of stored lipids and associated glycerol release in experimental metabolic models.
Fat oxidation
Experimental studies investigated changes in fat oxidation, a process through which fatty acids contribute to energy metabolism.
Receptor signalling
Researchers examined growth hormone receptor activity and beta-3 adrenergic-related signalling to better understand the fragment’s experimental mechanisms.
These are experimental research pathways, not established evidence that AOD-9604 causes weight loss or provides metabolic benefits in humans.
What has AOD-9604 research investigated?
AOD-9604 has been investigated in preclinical models and historical human clinical development programmes. Early experimental findings and later human outcomes need to be considered separately.
Heffernan et al. ยท International Journal of Obesity (2001)
Preclinical investigations examined fat oxidation, glycerol release and body-weight gain in experimental obesity models. Results suggested metabolic activity under the study conditions. Separate cell assays examined the fragment’s relationship to full-length growth hormone signalling.
Heffernan et al. ยท Endocrinology (2001)
A separate study investigated chronic AOD-9604 exposure in experimental obesity models, including beta-3 adrenergic receptor-related measurements. Findings indicated that its proposed mechanism was more complex than direct beta-3 receptor activation alone.
Stier et al. ยท Journal of Endocrinology and Metabolism (2013)
A publication summarised six historical randomised, double-blind, placebo-controlled human studies involving 893 adults. These investigations used oral or intravenous study products and examined safety and tolerability under controlled trial conditions.
Later obesity-development findings
A later 24-week Phase 2b obesity programme involving 536 participants did not demonstrate statistically significant weight loss. Development for that indication was discontinued. This is an important limitation when interpreting the earlier preclinical results.
Historical clinical studies used different formulations and routes from this separate lyophilised research vial. Their results do not verify the safety or performance of Halo Bio material.
AOD-9604 vs Human Growth Hormone
Although AOD-9604 was developed from a sequence region of human growth hormone, the two molecules have substantially different structures and cannot be treated as interchangeable.
| Characteristic | AOD-9604 | Human Growth Hormone |
|---|---|---|
| Peptide length | 16 amino acids | 191 amino acids |
| Molecular classification | Modified C-terminal fragment | Full-length hormone |
| Structural relationship | Based on hGH 177-191 with an added tyrosine | Complete hGH sequence |
| Research focus | Experimental lipid metabolism | Growth hormone physiology and endocrine signalling |
| Interchangeable? | No | No |
Findings involving the full-length hormone should not be attributed to its modified fragment without supporting experimental evidence.
Melbourne stock. Nationwide dispatch.
Halo Bio holds stock in Melbourne and offers same-day dispatch for eligible in-stock orders placed before 2pm on business days, subject to payment confirmation. Tracking information is provided during fulfilment, with delivery times dependent on destination and carrier.
AOD-9604 research FAQs
AOD-9604 is a synthetic 16-amino-acid peptide based on the C-terminal region of human growth hormone. It is also known as Tyr-hGH 177-191.
AOD originally referred to Anti-Obesity Drug, reflecting the compound’s historical research-development programme. The name does not establish an approved medical use.
Preclinical work investigated lipid metabolism, lipolysis, fat oxidation and energy-related measurements. Historical human development programmes also examined obesity-related outcomes.
No. Human growth hormone contains 191 amino acids, whereas AOD-9604 is a modified 16-amino-acid fragment with different molecular properties.
No. Despite encouraging findings in some preclinical studies, a later Phase 2b obesity-development programme did not demonstrate statistically significant weight loss.
The reported sequence is YLRIVQCRSVEGSCGF, containing 16 amino-acid residues and a disulphide bridge between two cysteines.
It represents the nominal quantity of AOD-9604 research material. The label alone does not establish measured content or purity.
Solvent compatibility must be established for the specific research formulation. Do not assume that another supplier’s acidic-solution instructions or generic reconstitution charts apply to Halo Bio material. Follow verified product-specific laboratory handling documentation.
No. Halo Bio supplies this material exclusively for laboratory research, not for consumption, injection, self-administration or clinical treatment.
Eligible in-stock orders placed before 2pm on business days are dispatched from Melbourne the same day following payment confirmation.
Independent scientific publications
- Heffernan MA et al. Chronic treatment with human growth hormone or a modified C-terminal fragment and effects on fat oxidation in experimental obesity models. International Journal of Obesity, 2001.
- Heffernan M et al. The effects of human GH and its lipolytic fragment AOD9604 on lipid metabolism in experimental models. Endocrinology, 2001.
- Stier H et al. Safety and tolerability of the hexadecapeptide AOD9604 in human clinical trials. Journal of Endocrinology and Metabolism, 2013.
- Misra M. Obesity pharmacotherapy: current perspectives and future considerations. Therapeutic Advances in Endocrinology and Metabolism, 2013.
- PubChem. AOD-9604 acetate, CID 168310522.
View molecular record โ
Research references describe historical experimental material and clinical formulations. They do not constitute laboratory verification of Halo Bio’s current product batch.
Laboratory research use only.
Not intended for human or animal consumption, injection, self-administration, diagnostic use or clinical treatment. Published experimental findings do not establish the identity, purity, sterility, safety or performance of this separately supplied AOD-9604 material. Refer to batch-specific documentation and verified laboratory handling instructions where available.